Interferon alfa in the treatment paradigm for non-muscle-invasive bladder cancer.

No abstract is available for this paper.

• Publication year

  2014

• Venue

  Urologic oncology

• Publication date

  Unknown publication date

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/j.urolonc.2013.02.010PMID 23628309
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology

  2012cited by this paper
• 1050 Bacillus Calmette-Guerin: One third dose versus full dose and one year versus three years of maintenance. Final results of an EORTC GU Cancers Group randomized trial in non muscle invasive bladder cancer

  2012cited by this paper
• Cancer statistics, 2012

  2012cited by this paper
• Maintenance therapy with bacillus Calmette‐Guérin Connaught strain clearly prolongs recurrence‐free survival following transurethral resection of bladder tumour for non‐muscle‐invasive bladder cancer

  2011cited by this paper
• Factors affecting response to bacillus Calmette-Guérin plus interferon for urothelial carcinoma in situ.

  2011cited by this paper
• EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder, the 2011 update.

  2011cited by this paper
• A review of current guidelines and best practice recommendations for the management of nonmuscle invasive bladder cancer by the International Bladder Cancer Group.

  2011cited by this paper
• Diminished efficacy of Bacille Calmette-Guérin among elderly patients with nonmuscle invasive bladder cancer.

  2011cited by this paper
• Randomized phase III trial on gemcitabine versus mytomicin in recurrent superficial bladder cancer: evaluation of efficacy and tolerance.

  2010cited by this paper
• Bacillus Calmette-Guérin with or without interferon α-2b and megadose versus recommended daily allowance vitamins during induction and maintenance intravesical treatment of nonmuscle invasive bladder cancer.

  2010cited by this paper
• Long-term efficacy results of EORTC genito-urinary group randomized phase 3 study 30911 comparing intravesical instillations of epirubicin, bacillus Calmette-Guérin, and bacillus Calmette-Guérin plus isoniazid in patients with intermediate- and high-risk stage Ta T1 urothelial carcinoma of the bladd

  2010cited by this paper
• Serum Th1 and Th2 cytokine balance in patients of superficial transitional cell carcinoma of bladder pre- and post-intravesical combination immunotherapy

  2010cited by this paper
• New insights in intravesical treatment for intermediate- and high-risk non-muscle-invasive urothelial bladder carcinoma.

  2010cited by this paper
• Re: Richard J. Sylvester, Maurizio A. Brausi, Wim J. Kirkels, et al. Long-term efficacy results of EORTC genito-urinary group randomized phase 3 study 30911 comparing intravesical instillations of epirubicin, bacillus Calmette-Guérin, and bacillus Calmette-Guérin plus isoniazid in patients with inte

  2010cited by this paper
• Gemcitabine versus bacille Calmette‐Guérin after initial bacille Calmette‐Guérin failure in non‐muscle‐invasive bladder cancer

  2010cited by this paper
• NCCN clinical practice guidelines in oncology: hepatobiliary cancers.

  2009cited by this paper
• Intravesical hyperthermia and mitomycin-C for carcinoma in situ of the urinary bladder: experience of the European Synergo® working party

  2009cited by this paper
• Combined thermo-chemotherapy for recurrent bladder cancer after bacillus Calmette-Guerin.

  2009cited by this paper
• Impact of previous bacille Calmette-Guérin failure pattern on subsequent response to bacille Calmette-Guérin plus interferon intravesical therapy.

  2008cited by this paper
• Clinical Practice Recommendations for the Management of Non–Muscle Invasive Bladder Cancer

  2008cited by this paper
• Intravesicle gemcitabine in management of BCG refractory superficial TCC of urinary bladder-our experience.

  2008cited by this paper
• Interferon-α Induces TRAIL Expression and Cell Death Via an IRF-1-Dependent Mechanism in Human Bladder Cancer Cells

  2007cited by this paper
• Interferon-alpha induces TRAIL expression and cell death via an IRF-1-dependent mechanism in human bladder cancer cells.

  2007cited by this paper
• The impact of age on the response of patients with superficial bladder cancer to intravesical immunotherapy.

  2006cited by this paper
• Final results from a national multicenter phase II trial of combination bacillus Calmette-Guérin plus interferon alpha-2B for reducing recurrence of superficial bladder cancer.

  2006cited by this paper
• Phase II trial of intravesical gemcitabine in bacille Calmette-Guérin-refractory transitional cell carcinoma of the bladder.

  2006cited by this paper
• Bacillus calmette-guerin versus chemotherapy for the intravesical treatment of patients with carcinoma in situ of the bladder: a meta-analysis of the published results of randomized clinical trials.

  2005cited by this paper
• Superficial Bladder Cancer Therapy

  2004cited by this paper
• Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand

  2004cited by this paper
• Intravesical bacille Calmette-Guérin versus mitomycin C in superficial bladder cancer: formal meta-analysis of comparative studies on tumor progression.

  2004cited by this paper
• Intravesical electromotive mitomycin C versus passive transport mitomycin C for high risk superficial bladder cancer: a prospective randomized study.

  2003cited by this paper
• Management of bacillus Calmette-Guerin (BCG) refractory superficial bladder cancer: results with intravesical BCG and Interferon combination therapy.

  2003cited by this paper
• Combined bacillus Calmette–Guerin and interferon use in superficial bladder cancer

  2003cited by this paper
• Bacillus Calmete-Guérin plus interferon-alpha2B intravesical therapy maintains an extended treatment plan for superficial bladder cancer with minimal toxicity.

  2003cited by this paper
• Phase I trial of intravesical gemcitabine in bacillus Calmette-Guérin-refractory transitional-cell carcinoma of the bladder.

  2002cited by this paper
• A randomized comparative dose‐ranging study of interferon‐α and mitomycin‐C as an internal control in primary or recurrent superficial transitional cell carcinoma of the bladder

  2002cited by this paper
• Intravesical bacillus Calmette-Guerin reduces the risk of progression in patients with superficial bladder cancer: a meta-analysis of the published results of randomized clinical trials.

  2002cited by this paper
• Perioperative single dose instillation of epirubicin or interferon-alpha after transurethral resection for the prophylaxis of primary superficial bladder cancer recurrence: a prospective randomized multicenter study--FinnBladder III long-term results.

  2002cited by this paper
• Salvage intravesical therapy with interferon-alpha 2b plus low dose bacillus Calmette-Guerin is effective in patients with superficial bladder cancer in whom bacillus Calmette-Guerin alone previously failed.

  2001cited by this paper
• EFFICACY AND SAFETY OF VALRUBICIN FOR THE TREATMENT OF BACILLUS CALMETTE-GUERIN REFRACTORY CARCINOMA IN SITU OF THE BLADDER

  2000cited by this paper
• Efficacy and safety of valrubicin for the treatment of Bacillus Calmette-Guerin refractory carcinoma in situ of the bladder. The Valrubicin Study Group.

  2000cited by this paper
• Maintenance bacillus Calmette-Guerin immunotherapy for recurrent TA, T1 and carcinoma in situ transitional cell carcinoma of the bladder: a randomized Southwest Oncology Group Study.

  2000cited by this paper
• Long-term results of intravesical bacillus Calmette-Guérin therapy for stage T1 superficial bladder cancer.

  2000cited by this paper
• Urological Survey: Abstracts: Principles of Oncology, and Tumors of Bladder, Penis and UrethraIntravesical Bacille Calmette-Guerin Induces the Antiangiogenic Chemokine Interferon-Inducible Protein 10

  1999cited by this paper
• 5-year followup of a randomized prospective study comparing mitomycin C and bacillus Calmette-Guerin in patients with superficial bladder carcinoma. Swedish-Norwegian Bladder Cancer Study Group.

  1999cited by this paper
• Effects of bacillus Calmette-Guèrin and interferon alpha-2B on cytokine production in human bladder cancer cell lines.

  1999cited by this paper
• IFN-alpha 2B enhances Th1 cytokine responses in bladder cancer patients receiving Mycobacterium bovis bacillus Calmette-Guérin immunotherapy.

  1999cited by this paper
• Role of IL-12 in the induction and potentiation of IFN-gamma in response to bacillus Calmette-Guérin.

  1999cited by this paper
• Interferon-alpha-mediated down-regulation of angiogenesis-related genes and therapy of bladder cancer are dependent on optimization of biological dose and schedule.

  1999cited by this paper
• Natural killer (NK) cell assay within bladder mucosa of patients bearing transitional cell carcinoma (TCC) after interferon (IFN) therapy: an immunohistochemical and ultrastructural study.

  1998cited by this paper
• Efficacy of escalating doses of intravesical interferon alpha-2b in reducing recurrence rate and progression in superficial transitional cell carcinoma.

  1998cited by this paper
• Prophylactic intracavitary treatment with interferon alpha increases interferon gamma production by peripheral blood mononuclear cells in patients with superficial transitional cell carcinoma of the bladder.

  1997cited by this paper
• Results at 43 months' follow-up of a double-blind, randomized, prospective clinical trial using intravesical interferon alpha-2b in the prophylaxis of stage pT1 transitional cell carcinoma of the bladder.

  1997cited by this paper
• Pharmacological biocompatibility between intravesical preparations of BCG and interferon-alpha 2B.

  1997cited by this paper
• Intravesical immunoprophylaxis in recurrent superficial bladder cancer (Stage T1): multicenter trial comparing bacille Calmette-Guérin and interferon-alpha.

  1997cited by this paper
• Urinary cytokines during intravesical bacillus Calmette-Guerin therapy for superficial bladder cancer: processing, stability and prognostic value.

  1996cited by this paper
• Prediction of response to treatment in superficial bladder carcinoma through pattern of interleukin-2 gene expression.

  1996cited by this paper
• Prophylaxis of superficial bladder cancer with mitomycin or interferon alfa-2b: results of a multicentric Italian study.

  1994cited by this paper
• Carcinoma in situ.

  1992cited by this paper
• A randomized controlled study of intravesical alpha-2b-interferon in carcinoma in situ of the bladder.

  1990cited by this paper
• A Randomized Controlled Study of Intravesical α−2b-Interferon in Carcinoma in Situ of the Bladder*

  1990cited by this paper
• Complications of Bacillus Calmette-Guerin immunotherapy: review of 2602 patients and comparison of chemotherapy complications.

  1989cited by this paper
• Alpha-interferon in superficial bladder cancer: a Northern California Oncology Group Study.

  1988influential reference
• Risks and benefits of repeated courses of intravesical bacillus Calmette-Guerin therapy for superficial bladder cancer.

  1987cited by this paper
• Long-term results and complications of intracavitary bacillus Calmette-Guerin therapy for bladder cancer.

  1984cited by this paper

• Navigating bladder preservation in Bacillus Calmette-Guérin-unresponsive disease: how much risk is too much?

  2026cites this paper
• Construction and Validation of a Prognostic Survival Prediction Model for NMIBC Patients Undergoing Radical Cystectomy

  2025cites this paper
• BCG and Alternative Therapies to BCG Therapy for Non-Muscle-Invasive Bladder Cancer

  2024cites this paper
• Alternative Therapy to Intravesical Bacillus Calmette–Guerin in Nonmuscle Invasive Bladder Cancer

  2024cites this paper
• Impact of the natural environmental factor - trematode Opisthorchis felineus on the system of regulation of proliferative activity of somatic cells

  2024cites this paper
• An evaluation of nadofaragene firadenovec-vncg for the treatment of high-risk BCG-unresponsive non-muscle-invasive bladder cancer

  2024cites this paper
• The Emerging Treatment of BCG (Bacillus Calmette-Guérin)-Unresponsive Non–Muscle-Invasive Bladder Cancer

  2024cites this paper
• Breaking Barriers: Modulation of Tumor Microenvironment to Enhance Bacillus Calmette–Guérin Immunotherapy of Bladder Cancer

  2024cites this paper
• Multidisciplinary consensus document on the current treatment of bacille Calmette-Guérin-unresponsive non-muscle invasive bladder tumor.

  2024cites this paper
• Mechanism of action of nadofaragene firadenovec-vncg

  2024cites this paper
• Metabolomic Signatures of Treatment Response in Bladder Cancer

  2023cites this paper
• BCG-Unresponsive Non-Muscle-Invasive Bladder Cancer: Current Treatment Landscape and Novel Emerging Molecular Targets

  2023cites this paper
• MicroRNA-370 as a negative regulator of signaling pathways in tumor cells

  2023cites this paper
• Immunotherapy in urothelial cancer: current status and future directions

  2023cites this paper
• Impact of Effective Intravesical Therapies on Quality of Life in Patients with Non-Muscle Invasive Bladder Cancer: A Systematic Review

  2022cites this paper
• From Interferon to Checkpoint Inhibition Therapy—A Systematic Review of New Immune-Modulating Agents in Bacillus Calmette–Guérin (BCG) Refractory Non-Muscle-Invasive Bladder Cancer (NMIBC)

  2022influential citation
• Immunotherapy of High Risk Non-Muscle Invasive Bladder Cancer

  2021cites this paper
• Robust Prognostic Subtyping of Muscle-Invasive Bladder Cancer Revealed by Deep Learning-Based Multi-Omics Data Integration

  2021cites this paper
• Effects of Mycobacterium bovis Calmette et Guérin (BCG) in oncotherapy: Bladder cancer and beyond.

  2021cites this paper
• The association of salvage intravesical therapy following BCG with pathologic outcomes and survival after radical cystectomy for patients with high-grade non-muscle invasive bladder cancer: A multi-institution analysis.

  2021cites this paper
• Role of tumor microenvironment in the efficacy of BCG therapy

  2020cites this paper
• Intravesical nadofaragene firadenovec gene therapy for BCG-unresponsive non-muscle-invasive bladder cancer: a single-arm, open-label, repeat-dose clinical trial.

  2020cites this paper
• WITHDRAWN: Recombinant BCG overexpressing a STING agonist elicits trained immunity and improved antitumor efficacy in non-muscle invasive bladder cancer

  2020cites this paper
• INHIBITION OF UROTHELIAL CARCINOMA BY TYPE I INTERFERON ACTIVATION OF THE INNATE AND ADAPTIVE IMMUNE RESPONSE

  2019cites this paper
• Inhibition of urothelial carcinoma through targeted type I interferon-mediated immune activation

  2019cites this paper
• miR-370 regulates ISG15 expression and influences IFN-α sensitivity in hepatocellular carcinoma cells

  2018cites this paper
• Mechanisms of BCG immunotherapy and its outlook for bladder cancer

  2018cites this paper
• The development of interferon-based gene therapy for BCG unresponsive bladder cancer: from bench to bedside

  2018cites this paper
• Updates on the use of intravesical therapies for non-muscle invasive bladder cancer: how, when and what

  2018cites this paper
• Advances and Perspectives in Urinary Bladder Cancer Nanotherapy

  2018cites this paper
• Protein Aggregate Magnesium-Ammonium Phospholinoleate-Palmitoleate Anhydride Immunomodulator

  2018cites this paper
• Intracavitary bacillus Calmette-Guérin for Superficial Bladder Tumors.

  2017cites this paper
• Intravesical rAd-IFNα/Syn3 for Patients With High-Grade, Bacillus Calmette-Guerin-Refractory or Relapsed Non-Muscle-Invasive Bladder Cancer: A Phase II Randomized Study.

  2017cites this paper
• Erratum to: Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of bladder carcinoma

  2017cites this paper
• Tackling non-muscle invasive bladder cancer in the clinic

  2017cites this paper
• Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of bladder carcinoma

  2017cites this paper
• A novel engineered interferon-α hybrid molecule increases anticancer efficacy of doxorubicin in breast cancer chemotherapy.

  2017cites this paper
• Lipopolysaccharide ‐ induced cytokine expression pattern in peripheral blood mononuclear cells in childhood obesity

  2016cites this paper
• Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of renal cell carcinoma

  2016cites this paper
• Future directions in bladder cancer immunotherapy: towards adaptive immunity.

  2016cites this paper
• Immunotherapy for genitourinary cancer: state of the art and new perspectives

  2016cites this paper
• Interferon-Related Depression: A Primer on Mechanisms, Treatment, and Prevention of a Common Clinical Problem

  2016cites this paper
• A pH-sensitive stearoyl-PEG-poly(methacryloyl sulfadimethoxine)-decorated liposome system for protein delivery: An application for bladder cancer treatment.

  2016cites this paper
• Lipopolysaccharide-induced cytokine expression pattern in peripheral blood mononuclear cells in childhood obesity.

  2016cites this paper
• The progress and prospects of routine prophylactic antiviral treatment in hepatitis B-related hepatocellular carcinoma.

  2016cites this paper
• Expert consensus document: Consensus statement on best practice management regarding the use of intravesical immunotherapy with BCG for bladder cancer

  2015cites this paper
• Intravesical immunotherapy in nonmuscle invasive bladder cancer

  2015influential citation
• Immunotherapy and Radiation – A New Combined Treatment Approach for Bladder Cancer?

  2015cites this paper
• Novel molecular targets for urothelial carcinoma

  2015cites this paper
• ISG15 as a novel prognostic biomarker for hepatitis B virus-related hepatocellular carcinoma.

  2015cites this paper
• Combination of IFNα and poly-I:C reprograms bladder cancer microenvironment for enhanced CTL attraction

  2015cites this paper
• Cancer immunology for the clinician.

  2015cites this paper
• Transcatheter arterial chemoembolization combined with interferon-α is safe and effective for patients with hepatocellular carcinoma after curative resection.

  2015cites this paper
• Intravenous 3-weekly paclitaxel and metronomic oral cyclophosphamide in patients with advanced urothelial cancer previously treated with gemcitabine and platinum

  2015cites this paper
• ISG 15 as a novel prognostic biomarker for hepatitis B virus-related hepatocellular carcinoma

  2015cites this paper
• The Role of Interferon in the Management of BCG Refractory Nonmuscle Invasive Bladder Cancer

  2015cites this paper
• Interferon-α and cyclooxygenase-2 inhibitor cooperatively mediates TRAIL-induced apoptosis in hepatocellular carcinoma.

  2015cites this paper
• TACE Combined with Interferon-α is Safe and Effective for HCC Patiens after Curative Resection

  2015cites this paper
• Role of antiviral therapy in reducing recurrence and improving survival in hepatitis B virus-associated hepatocellular carcinoma following curative resection (Review)

  2014cites this paper
• Expert review: an update in current and developing intravesical therapies for non-muscle-invasive bladder cancer

  2013cites this paper
• Maturation inside and outside bone marrow dendritic cells (BMDCs) modulated by interferon-α (IFN-α).

  2013cites this paper